Skip to content
OpenCapital
Get started

Innoviva, Inc. INVA Receivables Long Term Contracts Or Programs

Receivables Long Term Contracts Or Programs at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
——

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B—
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K—
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.41B+9.7%
P/E3.5×—
P/S4.2×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%—
Debt / equity0.2×—
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ReceivablesLongTermContractsOrPrograms.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s receivables long term contracts or programs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s receivables long term contracts or programs?
Innoviva, Inc. (INVA) reported receivables long term contracts or programs of $58.62M in Q1 2026.
How has Innoviva, Inc.'s receivables long term contracts or programs changed year-over-year?
Innoviva, Inc.'s receivables long term contracts or programs decreased by 4.3% year-over-year, from $61.26M to $58.62M.
What is the long-term trend for Innoviva, Inc.'s receivables long term contracts or programs?
Over 4 years (2021 to 2025), Innoviva, Inc.'s receivables long term contracts or programs has grown at a -14.8% compound annual growth rate (CAGR), from $110.71M to $58.35M.